Achievements

Here, you will find examples of investments made by MSBiV, as well as a complete list of projects in which MSBiV has invested directly or supported through its activities. We invite you to contact the individuals involved directly, or to contact us for more details.

Leap Medical [+]

Academic Partner: McGill University
Founders: Victor Lanzo and Rajeev Agarwal
Researchers: David Burns

MSBi Valorisation’s activities:

  • Strategic positioning of the detection technology
  • Structuring of a financing round including non-dilutive sources of funding
  • Board member position
Close

Academic Partner: McGill University

Founders: Victor Lanzo and Rajeev Agarwal

Researchers: David Burns

For more information

Leap Medical, a McGill University spin-off, is a medical device company dedicated to improving patient outcomes. The underlying technology for its first product, to non-invasively detect brain injuries and infections, was developed over a period of several years at the university. The company is currently focused on transitioning the core technology from its academic setting to an industrial one, and intends to complete its human clinical testing over the next months. Leap Medical is in the business of designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient’s medical condition.

MSBi Valorisation’s activities:

  • Strategic positioning of the detection technology in cooperation with the founders and other investors
  • Structuring of a financing round including non-dilutive sources of funding;
  • Funding
  • Board member position

Pakwa Technologies [+]

Academic Partner: University of Sherbrooke
Researchers: Patrick Vermette

MSBi Valorisation’s activities:

  • Supporting the grant application to MDEIE (PSVT-3)
  • Supporting the organization for the project
  • Supporting the team in securing seed stage financing for the launch of PAKWA
Close

Academic Partner: University of Sherbrooke

Researchers: Patrick Vermette

For more information

The purpose of this project is to develop a reliable measurement tool for the diagnosis of plaquettary activation. The project was presented at the proof of concept stage, and is now in clinical trials.
Result/Status: The initial clinical trial results look promising.

Potential: Development of diagnostic kits with for validation of the efficiency of medication prescribed before angioplasty (four million tests per year in the United States alone as per 2011.

MSBi Valorisation’s activities:

  • Supporting the grant application to MDEIE (PSVT-3), granted to the team in December 2008
  • Supporting the organization of the project
  • MSBi Valorisation is also supporting the team by securing seed stage financing for the launch of PAKWA.

Mimetogen [+]

Academic institution: McGill University and the Lady Davis Institute
Researcher: H. Uri Saragovi

MSBi Valorisation’s activities:

  • Creation of spin-off and seed funding
  • Support the strategic positioning of the technology
  • Support organization for MDEIE’s Entrepreneurial Assistance Program
  • Participation in Series B Funding

More information at: Mimetogen

Close

Academic Partner: McGill University and the Lady Davis Institut for Medical Research

Researchers: H. Uri Saragovi

For more information

Mimetogen is a clinical-stage biotechnology company specializing in ophthalmology, focused on developing novel small molecule compounds that mimic the effects of neurotrophins to treat dry eye and other degenerative ocular disorders.

Mimetogen was created in 2005, from technology developed at McGill University and the Lady Davis Institute for Medical Research in Montreal. Mimetogen’s investors are: VIMAC Milestone Medica Fund, iNovia Capital, MSBi Valorisation & Medwell Capital Corporation.

MSBi Valorisation’s activities included:

  • Creation of spin-off and seed funding
  • Support the strategic positioning of the technology
  • Support organization for MDEIE’s Entrepreneurial Assistance Program
  • Participation in Series B Funding

Achievements Attempts and Lost opportunities

Avian Flu [+]

Close

Optimized antiviral inhibitors targeting host cell furin proprotein convertases as an innovative therapeutic strategy against bacterial toxins and viral pathogens.

For more information : rpislariu@msbiv.com

Callio technologies [+]

Close

Information security management software.

For more information : www.callio.com

Fenretinide [+]

Close

Fenretinide: a new treatment for the pulmonary infections osteoporosis in Cystic Fibrosis patients.

For more information : www.flintbox.com/public/project/2480

Melatonine [+]

Close

First-in-class family of drug compounds with specificity on MT2 melatonin receptors whose therapeutic indications include insomnia, anxiety and depression.

For more information : rpislariu@msbiv.com

MOXXI Medical [+]

Close

Optimizes safety, quality of care and cost-effectiveness by delivering electronic prescriptions and computerized drug management.

Acquired by Fujitsu – www.fujitsu.com

For more information : www.moxxi.mcgill.ca

Reflex Photonics [+]

Close

Optical interconnects on chip.

For more information : www.reflexphotonics.com

Milestone [+]

Close

Drug development company developing a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

For more information : www.milestonepharma.com

Mimetogen [+]

Close

Mimetogen is a clinical-stage biotechnology company specializing in ophthalmology, focused on developing novel small molecule compounds that mimic the effects of neurotrophins to treat dry eye and other degenerative ocular disorders.

For more information : www.mimetogen.com

Leap Medical [+]

Close

Photonic technology for rapid, noninvasive screening of medical condition such as brain injuries and infections.

For more information : Case Study

SPACE Codesign [+]

Close

Simplifies electronic embedded system design.

For more information : www.spacecodesign.com

Widesail [+]

Close

Error correction technology for digital communications.

For more information : Case study

Lithotripeur [+]

Close

Generation of high-amplitude shock waves for non-invasive or minimally invasive therapeutic applications, like kidney stones removal or the treatment of chronic total occlusions.

For more information : elagace@msbiv.com

PACE4 [+]

Close

Selective inhibitors of the proprotein convertase PACE4 as effective anti-proliferative agents.

For more information : rpislariu@msbiv.com

iGF-Trap [+]

Close

Soluble Insulin Growth Factor (IGF) receptors as anti-angiogenic agents.

For more information : flemaitreauger@msbiv.com

Virtual Haydn [+]

Close

Virtual acoustic revisiting of the complete works of Haydn for solo keyboard.

For more information : www.music.mcgill.ca/thevirtualhaydn/

Plaquettary Activation Detection [+]

Close

Reliable measurement tool for the diagnosis of plaquettary activation.

For more information : Study case

Plastic Knowledge [+]

Close

Smart plastic materials designed to meet a wide range of critical performance and environmental parameters.

For more information : www.plastic-k.com

NexPlasmagen [+]

Close

Novel cold atmospheric plasma device for wound healing.

For more information : flemaitreauger@msbiv.com

Evanescent BioSensor [+]

Close

A new generation of biosensors for label-free and real-time in situ monitoring of multiple analytes ex vivo and in vivo.

For more information : dleconte@msbiv.com

Brain Vital [+]

Close

BrainVital develops a new approach to the treatment of Epilepsy and other neurological diseases.

For more information: www.brainvital.com

Needle-Free Vaccin [+]

Close

The project targets the development of a technology enabling DNA vaccine delivery triggering an immune response and conventional vaccine. This project is done in collaboration with GSK Biologicals and Aldevron two worldwide leader in this domain. The Charles River company also joined the project. MSBiV supports the maturation project granted by the MDEIE.

For more information (in french): MDEIE’s announcement

Monitoring System for BioProcesses [+]

Close

This project aims at designing and developing an efficient monitoring system for bioprocesses that will enable the implementation of control and online optimization of cell physiology and compounds production.

MSBiV is an accompanying organization as per the development project, in charge of assessing milestones.

For more information: Laboratory

Canetique Electrocatalyst [+]

Fermer

Canetique is making Fuel Cells commercially viable by developing affordable non-precious metal catalysts.

For more information: www.canetique.com